Caris Life Sciences (CAI) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $35.00 from $25.00 | Oct 14, 2026 |
| TD Cowen | Maintained | Buy | $36.00 from $30.00 | Oct 13, 2026 |
| UBS | Initiated Coverage | Neutral | $28.00 | Sep 9, 2026 |
| Evercore ISI Group | Maintained | Outperform | $26.00 from $25.00 | Aug 6, 2026 |
| BTIG | Maintained | Buy | $33.00 from $32.00 | Aug 6, 2026 |
| Evercore ISI Group | Maintained | Outperform | $25.00 from $30.00 | Jul 6, 2026 |
| BTIG | Maintained | Buy | $32.00 | Jul 2, 2026 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | Jun 2, 2026 |
| BTIG | Maintained | Buy | $32.00 from $38.00 | May 8, 2026 |
| JP Morgan | Maintained | Overweight | $30.00 from $35.00 | May 8, 2026 |
| Citigroup | Maintained | Buy | $28.00 from $35.00 | May 8, 2026 |
| Jefferies | Initiated Coverage | Buy | $28.00 | Apr 13, 2026 |
| Piper Sandler | Initiated Coverage | Neutral | $21.00 | Apr 10, 2026 |
| Evercore ISI Group | Maintained | Outperform | $30.00 from $34.00 | Apr 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $22.00 from $30.00 | Mar 13, 2026 |
| BTIG | Maintained | Buy | $38.00 from $45.00 | Feb 27, 2026 |
| Evercore ISI Group | Maintained | Outperform | $34.00 from $38.00 | Feb 27, 2026 |
| Baird | Maintained | Outperform | $28.00 from $26.00 | Feb 27, 2026 |
| Baird | Initiated Coverage | Outperform | $26.00 | Feb 17, 2026 |
| Canaccord Genuity | Maintained | Hold | $30.00 from $28.00 | Dec 22, 2025 |
Frequently asked questions
What is the price target for CAI stock?
The average 12-month analyst price target for Caris Life Sciences (CAI) is $31.60, with a high estimate of $36.00 and a low of $26.00, across 5 analysts.
Is CAI a buy, sell, or hold?
Analysts covering Caris Life Sciences currently average a Buy rating: 10 buy, 4 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CAI?
The average price target of $31.60 implies 4.45% upside from the last price of $30.26.
What is the latest analyst rating on CAI?
On Oct 14, 2026, JP Morgan maintained Caris Life Sciences at Overweight with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.